NCT04637438

Brief Summary

This pilot study aims to detect possible trends or signals suggesting efficacy of FMT on prevention of delay of POR, to determine the safety of FMT in post operative CD, and asses if a full randomised controlled trial is feasible in this setting. With microbiota analysis we aim to assess if changes in gut microbiota are related to disease course of CD after operation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
19mo left

Started May 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress76%
May 2021Dec 2027

First Submitted

Initial submission to the registry

October 21, 2020

Completed
29 days until next milestone

First Posted

Study publicly available on registry

November 19, 2020

Completed
6 months until next milestone

Study Start

First participant enrolled

May 18, 2021

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
4 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Expected
Last Updated

October 27, 2022

Status Verified

October 1, 2022

Enrollment Period

2.5 years

First QC Date

October 21, 2020

Last Update Submit

October 24, 2022

Conditions

Keywords

Fecal Microbiota Transplantation

Outcome Measures

Primary Outcomes (1)

  • Change in endoscopic Rutgeerts score between first and second colonoscopy

    Rutgeerts endoscopic score ranges from i0 indicating remission to i4 indicating severe post-operative relapse. Cut off value \> i1 will be used to compare number on patients in intervention group and in placebo group.

    1 year

Secondary Outcomes (10)

  • Safety of FMT using FinFMT-Questionnaire

    3 months, 12 months, 5 years

  • Clinical activity of Crohn's disease using Harwey-Bradshaw Index

    6 months, 12 months, 5 years

  • Histologic activity of Crohn's Disease using modified Global Histological Activity Score

    1 years, 5 years

  • Change of microbiota in stool samples and in intestinal biopsies

    6 weeks,12 weeks, 48 weeks, 5 years

  • Patient reported outcome

    12 weeks, 48 weeks,years 5

  • +5 more secondary outcomes

Study Arms (2)

Fecal Microbiota Transplantation

ACTIVE COMPARATOR
Other: Fecal Microbiota Transplantation

Plasebo

PLACEBO COMPARATOR
Other: Placebo

Interventions

FMT via colonoscopy

Fecal Microbiota Transplantation
PlaceboOTHER

Water infusion via colonoscopy

Plasebo

Eligibility Criteria

Age18 Years - 120 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Over 18 years
  • Able to provide written consent
  • Stricturing and/or fistulizing Crohn's disease needing ileocecal or ileal resection

You may not qualify if:

  • Pregnancy
  • Active infection, abscess or fistula at the time of the first colonoscopy
  • Life expectancy \<1 year
  • Unable to provide written consent
  • Use on antibiotics or probiotics at the time of first colonoscopy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Tampere University Hospital

Tampere, 33521, Finland

RECRUITING

Tampere University Hospital

Tampere, 33521, Finland

RECRUITING

MeSH Terms

Conditions

Crohn Disease

Interventions

Fecal Microbiota Transplantation

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

Biological TherapyTherapeutics

Central Study Contacts

Elina Jokinen, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor of Medical Science

Study Record Dates

First Submitted

October 21, 2020

First Posted

November 19, 2020

Study Start

May 18, 2021

Primary Completion

December 1, 2023

Study Completion (Estimated)

December 1, 2027

Last Updated

October 27, 2022

Record last verified: 2022-10

Data Sharing

IPD Sharing
Will not share

Locations